Legislation to further protect the American people from Big Pharma’s relentless price gouging is moving in the U.S. Senate.

Public Citizen is one of 40 organizations that sent a letter this week urging Sen. Chuck Schumer — the leader of the Democratic majority in the Senate — to include critical insulin reforms in this upcoming legislation.

Big Pharma has jacked up the price of insulin in the U.S. by as much as 1100% since the 1990s — despite low production costs.

As research from Public Citizen — in collaboration with Harvard University and Hunter College — has shown, 1.3 million Americans with diabetes have been forced to ration their insulin due to high prices.

And for those without insurance, this immoral — and possibly fatal — situation is even worse, with nearly 1 out 3 uninsured people with diabetes being forced to ration their insulin because of Big Pharma’s price gouging.

Over the past year, we have made big strides on this issue, winning a cap on monthly insulin costs for Medicare beneficiaries and forcing major manufacturers to dramatically lower prices of commonly used insulins.

Even more progress is needed to expand access and ensure fair and affordable pricing for insulin.

To the U.S. Senate:

Upcoming drug-pricing legislation must ensure access to insulin for everyone regardless of insurance status AND include controls on Big Pharma’s price gouging and anti-competitive tactics over insulin.

Click now to add your name.

Thanks for taking action.

For progress,

- Robert Weissman, President of Public Citizen

Public Citizen | 1600 20th Street NW | Washington DC 20009 | Unsubscribe